









Markets
/
Stocks
/
nasdaq-elvn
/

Enliven Therapeutics Inc

ELVN

19.925USD

+0.905+4.76%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.18BMarket Cap

LossP/E TTM



Enliven Therapeutics Inc

19.925

+0.905+4.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

186 / 507

Overall Ranking

333 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.667

Target Price

+120.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.

Overvalued

The company’s latest PE is -9.52, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 55.74M shares, increasing 0.11% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.40M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.48.

Financial Health

Currency: USD Updated：2025-09-17

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -9.52, which is 3.93% below the recent high of -9.89 and -17.24% above the recent low of -11.16.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 186/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.60, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Enliven Therapeutics Inc is 38.00, with a high of 52.00 and a low of 33.00.

Score

Industry at a Glance

Previous score

8.60

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

40.667

Target Price

+113.81%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Enliven Therapeutics Inc

ELVN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.81, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 20.88 and the support level at 17.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.39

Change

0.42

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.166

Sell

RSI(14)

51.153

Neutral

STOCH(KDJ)(9,3,3)

47.773

Buy

ATR(14)

1.143

High Vlolatility

CCI(14)

-30.261

Neutral

Williams %R

41.793

Buy

TRIX(12,20)

-0.123

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

19.167

Buy

MA10

19.487

Buy

MA20

19.949

Sell

MA50

20.228

Sell

MA100

19.929

Sell

MA200

20.570

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 97.05%, representing a quarter-over-quarter increase of 0.06%. The largest institutional shareholder is The Vanguard, holding a total of 2.40M shares, representing 4.06% of shares outstanding, with 0.54% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

7.96M

Fidelity Management & Research Company LLC

5.52M

-0.30%

Commodore Capital LP

4.67M

+11.18%

VR Adviser, LLC

4.03M

Fairmount Funds Management LLC

3.20M

Polar Capital LLP

2.37M

-1.02%

BlackRock Institutional Trust Company, N.A.

2.70M

+1.44%

The Vanguard Group, Inc.

Star Investors

1.97M

-0.17%

Janus Henderson Investors

1.57M

+17.92%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.29, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.